group_name,group_level,strata_name,strata_level,variable,variable_level,variable_type,estimate_type,estimate,cdm_name,generated_by
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,number subjects,NA,NA,count,22836,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,number records,NA,NA,count,22836,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_0_covid,NA,binary,count,1110,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_0_covid,NA,binary,%,4.86074619022596,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_0_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_0_malaria,NA,binary,%,0.00437905062182519,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_0_none,NA,binary,count,21167,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_0_none,NA,binary,%,92.6913645121738,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,479,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,2.09756524785427,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_0_rheumatoid_arthritis,NA,binary,count,559,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_0_rheumatoid_arthritis,NA,binary,%,2.44788929760028,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_30_covid,NA,binary,count,2110,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_30_covid,NA,binary,%,9.23979681205115,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_30_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_30_malaria,NA,binary,%,0.00437905062182519,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_30_none,NA,binary,count,19800,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_30_none,NA,binary,%,86.7052023121387,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,787,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,3.44631283937642,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_30_rheumatoid_arthritis,NA,binary,count,934,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_30_rheumatoid_arthritis,NA,binary,%,4.09003328078473,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_365_covid,NA,binary,count,2890,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_365_covid,NA,binary,%,12.6554562970748,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_365_malaria,NA,binary,count,3,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_365_malaria,NA,binary,%,0.0131371518654756,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_365_none,NA,binary,count,17557,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_365_none,NA,binary,%,76.8829917673848,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,2099,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,9.19162725521107,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_365_rheumatoid_arthritis,NA,binary,count,2493,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_365_rheumatoid_arthritis,NA,binary,%,10.9169732002102,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_7_covid,NA,binary,count,1904,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_7_covid,NA,binary,%,8.33771238395516,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_7_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_7_malaria,NA,binary,%,0.00437905062182519,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_7_none,NA,binary,count,20210,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_7_none,NA,binary,%,88.5006130670871,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,611,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,2.67559992993519,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_7_rheumatoid_arthritis,NA,binary,count,724,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,after_fda_retraction,indication_gap_7_rheumatoid_arthritis,NA,binary,%,3.17043265020144,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,number subjects,NA,NA,count,17245,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,number records,NA,NA,count,17245,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_0_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_0_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_0_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_0_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_0_none,NA,binary,count,16907,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_0_none,NA,binary,%,98.0400115975645,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,309,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,1.79182371701943,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_0_rheumatoid_arthritis,NA,binary,count,338,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_0_rheumatoid_arthritis,NA,binary,%,1.95998840243549,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_30_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_30_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_30_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_30_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_30_none,NA,binary,count,16637,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_30_none,NA,binary,%,96.4743403885184,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,560,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,3.24731806320673,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_30_rheumatoid_arthritis,NA,binary,count,608,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_30_rheumatoid_arthritis,NA,binary,%,3.52565961148159,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_365_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_365_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_365_malaria,NA,binary,count,2,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_365_malaria,NA,binary,%,0.0115975645114526,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_365_none,NA,binary,count,14945,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_365_none,NA,binary,%,86.6628008118295,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,2144,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,12.4325891562772,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_365_rheumatoid_arthritis,NA,binary,count,2298,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_365_rheumatoid_arthritis,NA,binary,%,13.325601623659,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_7_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_7_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_7_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_7_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_7_none,NA,binary,count,16823,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_7_none,NA,binary,%,97.5529138880835,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,388,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,2.2499275152218,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_7_rheumatoid_arthritis,NA,binary,count,422,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,before_pandemic,indication_gap_7_rheumatoid_arthritis,NA,binary,%,2.4470861119165,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,number subjects,NA,NA,count,9565,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,number records,NA,NA,count,9565,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_0_covid,NA,binary,count,94,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_0_covid,NA,binary,%,0.982749607945635,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_0_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_0_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_0_none,NA,binary,count,9382,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_0_none,NA,binary,%,98.086774699425,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,85,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,0.888656560376372,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_0_rheumatoid_arthritis,NA,binary,count,89,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_0_rheumatoid_arthritis,NA,binary,%,0.930475692629378,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_30_covid,NA,binary,count,391,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_30_covid,NA,binary,%,4.08782017773131,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_30_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_30_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_30_none,NA,binary,count,9003,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_30_none,NA,binary,%,94.1244119184527,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,165,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,1.72503920543649,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_30_rheumatoid_arthritis,NA,binary,count,171,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_30_rheumatoid_arthritis,NA,binary,%,1.787767903816,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_365_covid,NA,binary,count,393,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_365_covid,NA,binary,%,4.10872974385781,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_365_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_365_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_365_none,NA,binary,count,8603,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_365_none,NA,binary,%,89.9424986931521,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,521,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,5.446941975954,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_365_rheumatoid_arthritis,NA,binary,count,571,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_365_rheumatoid_arthritis,NA,binary,%,5.96968112911657,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_7_covid,NA,binary,count,346,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_7_covid,NA,binary,%,3.617354939885,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_7_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_7_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_7_none,NA,binary,count,9088,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_7_none,NA,binary,%,95.0130684788291,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,125,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,1.30684788290643,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_7_rheumatoid_arthritis,NA,binary,count,131,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Calendar time,during_hcq_use_for_covid,indication_gap_7_rheumatoid_arthritis,NA,binary,%,1.36957658128594,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,number subjects,NA,NA,count,2453,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,number records,NA,NA,count,2453,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_0_covid,NA,binary,count,1177,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_0_covid,NA,binary,%,47.9820627802691,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_0_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_0_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_0_none,NA,binary,count,1276,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_0_none,NA,binary,%,52.0179372197309,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_0_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_0_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_30_covid,NA,binary,count,2410,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_30_covid,NA,binary,%,98.2470444353852,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_30_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_30_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_30_none,NA,binary,count,43,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_30_none,NA,binary,%,1.75295556461476,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_30_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_30_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_365_covid,NA,binary,count,2453,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_365_covid,NA,binary,%,100,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_365_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_365_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_365_none,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_365_none,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_365_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_365_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_7_covid,NA,binary,count,2202,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_7_covid,NA,binary,%,89.7676314716673,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_7_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_7_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_7_none,NA,binary,count,251,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_7_none,NA,binary,%,10.2323685283327,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_7_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,covid,indication_gap_7_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,number subjects,NA,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,number records,NA,NA,count,7,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_0_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_0_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_0_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_0_malaria,NA,binary,%,14.2857142857143,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_0_none,NA,binary,count,6,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_0_none,NA,binary,%,85.7142857142857,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_0_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_0_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_30_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_30_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_30_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_30_malaria,NA,binary,%,14.2857142857143,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_30_none,NA,binary,count,6,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_30_none,NA,binary,%,85.7142857142857,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_30_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_30_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_365_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_365_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_365_malaria,NA,binary,count,5,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_365_malaria,NA,binary,%,71.4285714285714,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_365_none,NA,binary,count,2,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_365_none,NA,binary,%,28.5714285714286,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_365_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_365_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_7_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_7_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_7_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_7_malaria,NA,binary,%,14.2857142857143,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_7_none,NA,binary,count,6,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_7_none,NA,binary,%,85.7142857142857,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_7_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,malaria,indication_gap_7_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,number subjects,NA,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,number records,NA,NA,count,116,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_0_covid,NA,binary,count,27,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_0_covid,NA,binary,%,23.2758620689655,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_0_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_0_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_0_none,NA,binary,count,84,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_0_none,NA,binary,%,72.4137931034483,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_0_rheumatoid_arthritis,NA,binary,count,6,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_0_rheumatoid_arthritis,NA,binary,%,5.17241379310345,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_30_covid,NA,binary,count,91,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_30_covid,NA,binary,%,78.448275862069,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_30_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_30_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_30_none,NA,binary,count,22,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_30_none,NA,binary,%,18.9655172413793,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_30_rheumatoid_arthritis,NA,binary,count,12,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_30_rheumatoid_arthritis,NA,binary,%,10.3448275862069,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_365_covid,NA,binary,count,114,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_365_covid,NA,binary,%,98.2758620689655,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_365_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_365_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_365_none,NA,binary,count,2,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_365_none,NA,binary,%,1.72413793103448,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_365_rheumatoid_arthritis,NA,binary,count,34,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_365_rheumatoid_arthritis,NA,binary,%,29.3103448275862,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_7_covid,NA,binary,count,48,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_7_covid,NA,binary,%,41.3793103448276,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_7_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_7_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_7_none,NA,binary,count,62,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_7_none,NA,binary,%,53.448275862069,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_7_rheumatoid_arthritis,NA,binary,count,9,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,multiple,indication_gap_7_rheumatoid_arthritis,NA,binary,%,7.75862068965517,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,number subjects,NA,NA,count,31995,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,number records,NA,NA,count,31995,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_0_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_0_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_0_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_0_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_0_none,NA,binary,count,31995,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_0_none,NA,binary,%,100,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_0_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_0_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_30_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_30_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_30_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_30_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_30_none,NA,binary,count,31995,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_30_none,NA,binary,%,100,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_30_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_30_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_365_covid,NA,binary,count,486,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_365_covid,NA,binary,%,1.51898734177215,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_365_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_365_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_365_none,NA,binary,count,31509,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_365_none,NA,binary,%,98.4810126582279,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_365_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_365_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_7_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_7_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_7_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_7_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_7_none,NA,binary,count,31995,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_7_none,NA,binary,%,100,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_7_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,none,indication_gap_7_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,number subjects,NA,NA,count,15075,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,number records,NA,NA,count,15075,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_0_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_0_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_0_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_0_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_0_none,NA,binary,count,14095,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_0_none,NA,binary,%,93.4991708126037,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,873,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,5.7910447761194,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_0_rheumatoid_arthritis,NA,binary,count,980,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_0_rheumatoid_arthritis,NA,binary,%,6.50082918739635,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_30_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_30_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_30_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_30_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_30_none,NA,binary,count,13374,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_30_none,NA,binary,%,88.7164179104478,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,1512,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,10.0298507462687,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_30_rheumatoid_arthritis,NA,binary,count,1701,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_30_rheumatoid_arthritis,NA,binary,%,11.2835820895522,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_365_covid,NA,binary,count,230,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_365_covid,NA,binary,%,1.5257048092869,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_365_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_365_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_365_none,NA,binary,count,9592,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_365_none,NA,binary,%,63.6285240464345,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,4764,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,31.6019900497512,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_365_rheumatoid_arthritis,NA,binary,count,5328,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_365_rheumatoid_arthritis,NA,binary,%,35.3432835820896,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_7_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_7_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_7_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_7_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_7_none,NA,binary,count,13807,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_7_none,NA,binary,%,91.5887230514096,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,1124,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,7.45605306799337,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_7_rheumatoid_arthritis,NA,binary,count,1268,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Indication,rheumatoid_arthritis,indication_gap_7_rheumatoid_arthritis,NA,binary,%,8.41127694859038,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,number subjects,NA,NA,count,49646,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,number records,NA,NA,count,49646,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_0_covid,NA,binary,count,1204,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_0_covid,NA,binary,%,2.42517020505177,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_0_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_0_malaria,NA,binary,%,0.00201426096765097,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_0_none,NA,binary,count,47456,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_0_none,NA,binary,%,95.5887684808444,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,873,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,1.7584498247593,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_0_rheumatoid_arthritis,NA,binary,count,986,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_0_rheumatoid_arthritis,NA,binary,%,1.98606131410386,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_30_covid,NA,binary,count,2501,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_30_covid,NA,binary,%,5.03766668009507,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_30_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_30_malaria,NA,binary,%,0.00201426096765097,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_30_none,NA,binary,count,45440,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_30_none,NA,binary,%,91.52801837006,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,1512,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,3.04556258308827,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_30_rheumatoid_arthritis,NA,binary,count,1713,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_30_rheumatoid_arthritis,NA,binary,%,3.45042903758611,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_365_covid,NA,binary,count,3283,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_365_covid,NA,binary,%,6.61281875679813,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_365_malaria,NA,binary,count,5,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_365_malaria,NA,binary,%,0.0100713048382548,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_365_none,NA,binary,count,41105,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_365_none,NA,binary,%,82.7961970752931,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,4764,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,9.59593924988922,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_365_rheumatoid_arthritis,NA,binary,count,5362,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_365_rheumatoid_arthritis,NA,binary,%,10.8004673085445,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_7_covid,NA,binary,count,2250,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_7_covid,NA,binary,%,4.53208717721468,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_7_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_7_malaria,NA,binary,%,0.00201426096765097,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_7_none,NA,binary,count,46121,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_7_none,NA,binary,%,92.8997300890303,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,1124,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,2.26402932763969,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_7_rheumatoid_arthritis,NA,binary,count,1277,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_hydroxychloroquine,Overall,Overall,indication_gap_7_rheumatoid_arthritis,NA,binary,%,2.57221125569029,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,number subjects,NA,NA,count,15206,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,number records,NA,NA,count,15206,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_0_covid,NA,binary,count,10,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_0_covid,NA,binary,%,0.0657635144022096,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_0_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_0_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_0_none,NA,binary,count,14440,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_0_none,NA,binary,%,94.9625147967907,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,649,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,4.26805208470341,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_0_rheumatoid_arthritis,NA,binary,count,757,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_0_rheumatoid_arthritis,NA,binary,%,4.97829804024727,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_30_covid,NA,binary,count,91,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_30_covid,NA,binary,%,0.598447981060108,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_30_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_30_malaria,NA,binary,%,0.00657635144022097,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_30_none,NA,binary,count,13879,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_30_none,NA,binary,%,91.2731816388268,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,1056,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,6.94462712087334,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_30_rheumatoid_arthritis,NA,binary,count,1242,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_30_rheumatoid_arthritis,NA,binary,%,8.16782848875444,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_365_covid,NA,binary,count,628,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_365_covid,NA,binary,%,4.12994870445877,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_365_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_365_malaria,NA,binary,%,0.00657635144022097,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_365_none,NA,binary,count,11730,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_365_none,NA,binary,%,77.1406023937919,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,2540,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,16.7039326581613,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_365_rheumatoid_arthritis,NA,binary,count,2961,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_365_rheumatoid_arthritis,NA,binary,%,19.4725766144943,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_7_covid,NA,binary,count,25,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_7_covid,NA,binary,%,0.164408786005524,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_7_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_7_malaria,NA,binary,%,0.00657635144022097,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_7_none,NA,binary,count,14222,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_7_none,NA,binary,%,93.5288701828226,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,816,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,5.36630277522031,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_7_rheumatoid_arthritis,NA,binary,count,959,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,after_fda_retraction,indication_gap_7_rheumatoid_arthritis,NA,binary,%,6.30672103117191,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,number subjects,NA,NA,count,18770,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,number records,NA,NA,count,18770,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_0_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_0_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_0_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_0_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_0_none,NA,binary,count,18202,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_0_none,NA,binary,%,96.97389451252,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,527,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,2.80767181672882,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_0_rheumatoid_arthritis,NA,binary,count,568,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_0_rheumatoid_arthritis,NA,binary,%,3.02610548748002,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_30_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_30_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_30_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_30_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_30_none,NA,binary,count,17773,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_30_none,NA,binary,%,94.6883324453916,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,925,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,4.92807671816729,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_30_rheumatoid_arthritis,NA,binary,count,997,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_30_rheumatoid_arthritis,NA,binary,%,5.31166755460842,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_365_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_365_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_365_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_365_malaria,NA,binary,%,0.0053276505061268,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_365_none,NA,binary,count,15586,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_365_none,NA,binary,%,83.0367607884923,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,2969,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,15.8177943526905,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_365_rheumatoid_arthritis,NA,binary,count,3183,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_365_rheumatoid_arthritis,NA,binary,%,16.9579115610016,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_7_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_7_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_7_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_7_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_7_none,NA,binary,count,18049,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_7_none,NA,binary,%,96.1587639850826,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,664,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,3.53755993606819,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_7_rheumatoid_arthritis,NA,binary,count,721,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,before_pandemic,indication_gap_7_rheumatoid_arthritis,NA,binary,%,3.84123601491742,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,number subjects,NA,NA,count,3521,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,number records,NA,NA,count,3521,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_0_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_0_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_0_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_0_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_0_none,NA,binary,count,3370,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_0_none,NA,binary,%,95.711445612042,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,136,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,3.86253905140585,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_0_rheumatoid_arthritis,NA,binary,count,151,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_0_rheumatoid_arthritis,NA,binary,%,4.28855438795797,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_30_covid,NA,binary,count,2,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_30_covid,NA,binary,%,0.0568020448736154,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_30_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_30_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_30_none,NA,binary,count,3283,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_30_none,NA,binary,%,93.2405566600398,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,214,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,6.07781880147685,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_30_rheumatoid_arthritis,NA,binary,count,236,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_30_rheumatoid_arthritis,NA,binary,%,6.70264129508662,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_365_covid,NA,binary,count,4,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_365_covid,NA,binary,%,0.113604089747231,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_365_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_365_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_365_none,NA,binary,count,2892,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_365_none,NA,binary,%,82.1357568872479,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,561,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,15.9329735870491,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_365_rheumatoid_arthritis,NA,binary,count,626,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_365_rheumatoid_arthritis,NA,binary,%,17.7790400454416,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_7_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_7_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_7_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_7_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_7_none,NA,binary,count,3332,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_7_none,NA,binary,%,94.6322067594433,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,170,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,4.82817381425731,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_7_rheumatoid_arthritis,NA,binary,count,189,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Calendar time,during_hcq_use_for_covid,indication_gap_7_rheumatoid_arthritis,NA,binary,%,5.36779324055666,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,number subjects,NA,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,number records,NA,NA,count,70,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_0_covid,NA,binary,count,5,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_0_covid,NA,binary,%,7.14285714285714,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_0_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_0_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_0_none,NA,binary,count,65,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_0_none,NA,binary,%,92.8571428571429,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_0_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_0_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_30_covid,NA,binary,count,51,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_30_covid,NA,binary,%,72.8571428571429,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_30_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_30_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_30_none,NA,binary,count,19,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_30_none,NA,binary,%,27.1428571428571,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_30_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_30_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_365_covid,NA,binary,count,70,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_365_covid,NA,binary,%,100,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_365_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_365_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_365_none,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_365_none,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_365_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_365_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_7_covid,NA,binary,count,14,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_7_covid,NA,binary,%,20,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_7_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_7_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_7_none,NA,binary,count,56,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_7_none,NA,binary,%,80,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_7_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,covid,indication_gap_7_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,number subjects,NA,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,number records,NA,NA,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_0_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_0_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_0_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_0_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_0_none,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_0_none,NA,binary,%,100,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_0_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_0_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_30_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_30_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_30_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_30_malaria,NA,binary,%,100,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_30_none,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_30_none,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_30_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_30_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_365_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_365_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_365_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_365_malaria,NA,binary,%,100,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_365_none,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_365_none,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_365_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_365_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_7_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_7_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_7_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_7_malaria,NA,binary,%,100,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_7_none,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_7_none,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_7_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,malaria,indication_gap_7_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,number subjects,NA,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,number records,NA,NA,count,59,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_0_covid,NA,binary,count,5,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_0_covid,NA,binary,%,8.47457627118644,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_0_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_0_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_0_none,NA,binary,count,51,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_0_none,NA,binary,%,86.4406779661017,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_0_rheumatoid_arthritis,NA,binary,count,4,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_0_rheumatoid_arthritis,NA,binary,%,6.77966101694915,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_30_covid,NA,binary,count,42,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_30_covid,NA,binary,%,71.1864406779661,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_30_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_30_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_30_none,NA,binary,count,16,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_30_none,NA,binary,%,27.1186440677966,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_30_rheumatoid_arthritis,NA,binary,count,8,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_30_rheumatoid_arthritis,NA,binary,%,13.5593220338983,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_365_covid,NA,binary,count,56,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_365_covid,NA,binary,%,94.9152542372881,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_365_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_365_malaria,NA,binary,%,1.69491525423729,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_365_none,NA,binary,count,2,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_365_none,NA,binary,%,3.38983050847458,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_365_rheumatoid_arthritis,NA,binary,count,23,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_365_rheumatoid_arthritis,NA,binary,%,38.9830508474576,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_7_covid,NA,binary,count,11,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_7_covid,NA,binary,%,18.6440677966102,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_7_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_7_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_7_none,NA,binary,count,44,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_7_none,NA,binary,%,74.5762711864407,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_7_rheumatoid_arthritis,NA,binary,count,5,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,multiple,indication_gap_7_rheumatoid_arthritis,NA,binary,%,8.47457627118644,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,number subjects,NA,NA,count,18247,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,number records,NA,NA,count,18247,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_0_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_0_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_0_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_0_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_0_none,NA,binary,count,18247,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_0_none,NA,binary,%,100,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_0_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_0_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_30_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_30_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_30_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_30_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_30_none,NA,binary,count,18247,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_30_none,NA,binary,%,100,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_30_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_30_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_365_covid,NA,binary,count,259,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_365_covid,NA,binary,%,1.41941141009481,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_365_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_365_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_365_none,NA,binary,count,17988,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_365_none,NA,binary,%,98.5805885899052,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_365_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_365_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_7_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_7_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_7_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_7_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_7_none,NA,binary,count,18247,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_7_none,NA,binary,%,100,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_7_rheumatoid_arthritis,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,none,indication_gap_7_rheumatoid_arthritis,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,number subjects,NA,NA,count,19120,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,number records,NA,NA,count,19120,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_0_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_0_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_0_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_0_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_0_none,NA,binary,count,17648,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_0_none,NA,binary,%,92.3012552301255,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,1312,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,6.86192468619247,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_0_rheumatoid_arthritis,NA,binary,count,1472,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_0_rheumatoid_arthritis,NA,binary,%,7.69874476987448,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_30_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_30_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_30_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_30_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_30_none,NA,binary,count,16653,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_30_none,NA,binary,%,87.097280334728,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,2195,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,11.4801255230126,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_30_rheumatoid_arthritis,NA,binary,count,2467,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_30_rheumatoid_arthritis,NA,binary,%,12.902719665272,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_365_covid,NA,binary,count,247,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_365_covid,NA,binary,%,1.2918410041841,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_365_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_365_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_365_none,NA,binary,count,12218,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_365_none,NA,binary,%,63.9016736401674,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,6070,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,31.7468619246862,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_365_rheumatoid_arthritis,NA,binary,count,6747,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_365_rheumatoid_arthritis,NA,binary,%,35.2876569037657,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_7_covid,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_7_covid,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_7_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_7_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_7_none,NA,binary,count,17256,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_7_none,NA,binary,%,90.2510460251046,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,1650,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,8.62970711297071,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_7_rheumatoid_arthritis,NA,binary,count,1864,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Indication,rheumatoid_arthritis,indication_gap_7_rheumatoid_arthritis,NA,binary,%,9.7489539748954,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,number subjects,NA,NA,count,37497,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,number records,NA,NA,count,37497,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_0_covid,NA,binary,count,10,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_0_covid,NA,binary,%,0.0266688001706803,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_0_malaria,NA,binary,count,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_0_malaria,NA,binary,%,0,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_0_none,NA,binary,count,36012,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_0_none,NA,binary,%,96.039683174654,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,count,1312,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_0_rheumatoid_arthristis_no_covid,NA,binary,%,3.49894658239326,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_0_rheumatoid_arthritis,NA,binary,count,1476,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_0_rheumatoid_arthritis,NA,binary,%,3.93631490519242,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_30_covid,NA,binary,count,93,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_30_covid,NA,binary,%,0.248019841587327,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_30_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_30_malaria,NA,binary,%,0.00266688001706803,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_30_none,NA,binary,count,34935,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_30_none,NA,binary,%,93.1674533962717,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,count,2195,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_30_rheumatoid_arthristis_no_covid,NA,binary,%,5.85380163746433,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_30_rheumatoid_arthritis,NA,binary,count,2475,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_30_rheumatoid_arthritis,NA,binary,%,6.60052804224338,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_365_covid,NA,binary,count,632,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_365_covid,NA,binary,%,1.685468170787,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_365_malaria,NA,binary,count,2,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_365_malaria,NA,binary,%,0.00533376003413606,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_365_none,NA,binary,count,30208,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_365_none,NA,binary,%,80.5611115555911,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,count,6070,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_365_rheumatoid_arthristis_no_covid,NA,binary,%,16.187961703603,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_365_rheumatoid_arthritis,NA,binary,count,6770,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_365_rheumatoid_arthritis,NA,binary,%,18.0547777155506,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_7_covid,NA,binary,count,25,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_7_covid,NA,binary,%,0.0666720004267008,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_7_malaria,NA,binary,count,1,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_7_malaria,NA,binary,%,0.00266688001706803,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_7_none,NA,binary,count,35603,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_7_none,NA,binary,%,94.9489292476731,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,count,1650,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_7_rheumatoid_arthristis_no_covid,NA,binary,%,4.40035202816225,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_7_rheumatoid_arthritis,NA,binary,count,1869,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
Cohort name,new_users_methotrexate,Overall,Overall,indication_gap_7_rheumatoid_arthritis,NA,binary,%,4.98439875190015,PHARMETRICS,DrugUtilisation_0.2.1_summariseIndication
